ScaleReady Awards G-Rex® Grant to ImmunoScape

ST. PAUL, Minn., Sept. 18, 2024 - ScaleReady™, in partnership with Wilson Wolf Manufacturing, Bio-Techne Corporation, and CellReady™, has awarded a $250,000 G-Rex® Grant to ImmunoScape Pte. Ltd., a company specializing in TCR-T therapies. This grant will support the development and IND enabling studies of ImmunoScape's WT1-targeted TCR-T cell therapy.

Dr. Tania Ribeiro, Senior Director and Head of CMC at ImmunoScape, expressed gratitude for the grant, underscoring its importance in reducing the time and cost associated with bringing their advanced therapy into clinical settings. John Wilson, CEO of Wilson Wolf and co-inventor of G-Rex®, echoed this sentiment, emphasizing that the grant aims to accelerate the generation of critical clinical data for investors.

The grant will enable ImmunoScape to advance its pre-clinical process development. This includes utilizing Wilson Wolf's closed-system G-Rex® bioreactors. The company will also gain early access to Bio-Techne's ProPak™ GMP Cytokines, designed to streamline reagent preparation and administration in GMP manufacturing. These new products will help ImmunoScape reduce costs and simplify their processes, minimizing variability.

Moreover, the grant will support the technology transfer of their G-Rex-centric manufacturing process to their CDMO partner. This will involve training and engineering runs, which will be instrumental in creating the manufacturing batch records required for an IND data package submission to the FDA, planned for 2026.

The G-Rex Grant Program, a $20 million initiative by ScaleReady, aims to advance cell and gene-modified cell therapy (CGT) development and manufacturing. Each grant, valued at up to $300,000, provides recipients with access to a consortium of partners offering tools, technologies, and expertise in cGMP manufacturing, regulatory affairs, and CGT business operations.

ImmunoScape is focused on developing next-generation TCR-T cell therapies for solid tumors, leveraging Deep Immunomics and AI-driven insights to identify TCRs with significant therapeutic potential. With multiple programs in various stages of development, the company is preparing for clinical trials and exploring strategic partnerships to expand their reach.

ScaleReady provides a G-Rex centric manufacturing platform for CGT drug product development, currently utilized by over 800 organizations. The platform supports around 50% of CGT clinical trials and is essential in the production of four commercially approved CGT drugs. By leveraging ScaleReady's expertise, CGT entities can save substantial time and resources in their commercialization efforts.

Wilson Wolf Manufacturing aims to simplify CGT therapy research and production through scalable G-Rex® technology, which is globally used in a range of applications from research to commercial drug production. The company is dedicated to offering hope to cancer patients through these innovations.

Bio-Techne Corporation, a global life sciences company, provides innovative tools and bioactive reagents for research and clinical diagnostics. In collaboration with Wilson Wolf, Bio-Techne develops products tailored to G-Rex® Bioreactors, including right-sized reagent quantities for high-throughput closed-system manufacturing.

CellReady LLC, the first G-Rex® centric CDMO, specializes in the development and manufacturing of cell and gene-modified cell therapies. The company offers comprehensive services to support the commercialization of these therapies, aiming to provide hope for cancer patients through their G-Rex® processes.